IL15 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, HODHBt enhanced the ability of IL-15-activated NK cells to kill HIV-infected CD4 T cells and different tumor cell lines, including chronic myelogenous leukemia, ovarian carcinoma, and glioblastoma cell lines.